BioXcel Therapeutics is an American clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. It was incorporated in 2017 and is headquartered in New Haven, Connecticut.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
BioXcel Therapeutics news
11.05.2022
BioXcel Therapeutics' GAAP loss for 3 months of 2022 was $31.472 million, up 19.3% from $26.376 million in the previous year.
Source: 
ir.bioxceltherapeutics.com
ir.bioxceltherapeutics.com
10.03.2022
BioXcel Therapeutics' GAAP loss for 2021 was $106.931 million, up 30.1% from $82.169 million the previous year.
Source: ir.bioxceltherapeutics.com
ir.bioxceltherapeutics.com
11.11.2021
BioXcel Therapeutics' GAAP loss for 9M 2021 was $80.806 million, up 32.3% from $61.083 million in the prior year.
Source: ir.bioxceltherapeutics.com
ir.bioxceltherapeutics.com
10.08.2021
BioXcel Therapeutics' GAAP loss for 6M 2021 was $53.995 million, up 48.6% from $36.33 million in the previous year.
Source: ir.bioxceltherapeutics.com
ir.bioxceltherapeutics.com
General information
| Company name | BioXcel Therapeutics |
|---|---|
| Tags | #artificial intelligence, #pharmacy, #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States |
| Mailing address | 555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States |
| Website | ir.bioxceltherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 